Skip to main content
CPIX logo

CPIX

Cumberland Pharmaceuticals Inc
$6.16 -0.21 (-3.30%) At close · Jul 6
Market Cap
$92.30M
Shares
14,983,107

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$6.16 Open$6.30 Day$6.04–6.75 52W$1.85–7.36 Avg vol 30d71K Short int339K · 2.3% float · 6.3d Short vol24% Last earningsMay 5, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 8
Equibles Rating blended score · not investment advice
Overall
Strong Buy
Technical · trend & momentum Buy
50 / 200-day cross no cross
+ Price vs 200-day avg +59% above
+ Price vs 50-day avg +14% above
RSI (14) 54 · neutral
+ MACD trend positive
52-week position 78% · mid-range
Sentiment · smart money Bullish
Trend (MA cross) 50d $5 › 200d $4 — 50d above 200d
+ Institutional flow +7% holders QoQ · +8 funds added
Insider flow No net insider activity over 90 days
+ Short interest 2.26% of float · ▼ -4.5% MoM · 6.3 days cover
Volume signal Volume near normal
Institution breadth 30 holders — mid 3-yr range
Fundamentals Excellent
+ Revenue growth +17% Y/Y
+ EPS growth +59% Y/Y
+ Free cash flow $4.8M
+ Buyback $2.1M remaining
+ Balance sheet net cash $11.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 4, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 8, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Technicals

      trend & momentum for long-term holders Buy
      0 · 3 · 3
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      +59% above Bullish
      Price vs 50-day avg
      +14% above Bullish
      RSI (14)
      54 · neutral Neutral
      MACD trend
      positive Bullish
      52-week position
      78% · mid-range Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $5 › 200d $4 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +8 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      2.26% of float · ▼ -4.5% MoM · 6.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      30 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $2 Now $6 · 78% 52-wk high $7
      vs 200-day avg +59% vs 50-day avg +14%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CPIX
      Cumberland Pharmaceuticals Inc
      this stock
      $92.30M +54.8% +16.7% 2.3%
      TAK
      Takeda Pharmaceutical Co Ltd
      $53.37B +8.3% 0.2%
      GALDY
      Galderma Group AG/ADR
      $52.48B +8.0% 0.0%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      $45.13B 0.0%
      HLN
      Haleon plc
      $43.25B -2.9% 0.2%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      30
      % held
      19.4%
      Net QoQ
      -117.6K sh
      Top holder
      Ikarian Capital, LLC
      Held Float
      View
      Held by Funds
      Fund positions
      28
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      338.8K
      Days to cover
      6.3d
      Change
      -16.1K sh
      View
      Short Volume
      Short vol %
      24%
      As of
      Jul 6, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      172
      Value
      $1.0K
      As of
      Jun 5, 2026
      View
      Off-Exchange
      Off-exchange %
      58.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $44.5M
      Net income (FY)
      $-2.8M
      EPS diluted
      $-0.19
      View
      Buybacks
      Authorized
      $10.0M
      Remaining
      $2.1M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 1, 2026
      This year
      10
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CPIX -8.7% +5.5% +24.4% -4.9% +54.8%
      SPY +1.4% -1.3% +8.0% -0.3% +9.2%
      vs SPY -10.2% +6.7% +16.4% -4.7% +45.6%

      Capital returns

      Buyback program · as of Mar 31, 2026
      Authorized
      $10.00M
      Spent (derived)
      $7.90M
      Remaining
      $2.10M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1087294 CUSIP 230770109 Visit website Investor relations